Huffpost Business

Pfizer, Wyeth In Talks For $60B Merger

Posted: Updated:

Pfizer Inc. is in talks to acquire rival drug maker Wyeth in a deal that could be valued at more than $60 billion, said people familiar with the matter.

A combination of these two U.S. pharmaceutical giants would redraw the boundaries of the global drug industry, which has suffered from flagging product development and high fixed costs. It would also represent a high-stakes gambit for Pfizer, which has been stung in the past by expensive acquisitions.

The two sides have been in discussions for months and a deal isn't imminent, the people said. Given recent market volatility and overall economic uncertainty, the talks are especially fragile and could collapse, the people warned.

Read the whole story at Wall Street Journal

Around the Web

A Pfizer-Wyeth merger would not work well - Aug. 24, 2007

A Pfizer-Wyeth Merger Isn't the Cure-All - BusinessWeek

Pfizer, Wyeth merger bad idea? - FiercePharma

A Pfizer-Wyeth Merger Isn't the Cure-All

Deals of the Day: Thain Out; Wyeth in Talks; Cubs Pick a Winner

Barclays drops again but drugs soar on $60bn merger reports